Peery, Robert C.Liu, Jing-YuanZhang, Jian-Ting2018-03-142018-03-142017-10Peery, R. C., Liu, J.-Y., & Zhang, J.-T. (2017). Targeting survivin for therapeutic discovery: past, present, and future promises. Drug Discovery Today, 22(10), 1466–1477. https://doi.org/10.1016/j.drudis.2017.05.009https://hdl.handle.net/1805/15547Survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, is overexpressed in cells of almost all cancers but not in most normal tissues in adults. Survivin expression is required for cancer cell survival and knocking down its expression or inhibiting its function using molecular approaches results in spontaneous apoptosis. Thus, survivin is an attractive and perhaps ideal target for cancer drug discovery. However, a US Food and Drug Administration (FDA)-approved drug targeting survivin has yet to emerge. In this Foundation Review, we examine and evaluate various strategies that have been used to target survivin and the stages of each survivin inhibitor to help understand this lack of success. We also provide future perspectives moving forward in targeting survivin for drug discovery.enPublisher Policysurvivincancer therapeuticsdrug resistanceArticle